Nachrichten zur Agios Pharmaceuticals Aktie

Minneapolis (www.aktiencheck.de) - Ionis Pharmaceuticals-Aktienanalyse von Piper Sandler:Piper-Sandler-Analystin Allison Bratzel habe nach der Q4-Berichterstattung das Kursziel für die Aktie von…

AGIO beats fourth-quarter estimates for both the top and bottom lines as Pyrukynd sales jump 49% year over year.…

Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…

Agios Pharmaceuticals (AGIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings…

…

Agios Pharmaceuticals stock soars after FDA approves AQVESME for thalassemia…

Agios Pharmaceuticals wins FDA approval for Aqvesme in alpha- and beta-thalassemia, making mitapivat the only approved option, despite a new…

Bad Marienberg (www.aktiencheck.de)???????? Ionis Pharmaceuticals hebt ab: RBC Capital sieht neues Kursziel 95 USD und enormes MarktpotenzialIonis Pharmaceuticals Inc. (ISIN:…

New York (www.aktiencheck.de) - Ionis Pharmaceuticals-Aktienanalyse von Goldman Sachs:Salveen Richter von Goldman Sachs stuft die Aktie von Ionis Pharmaceuticals Inc.…

London (www.aktiencheck.de) - Ionis Pharmaceuticals-Aktienanalyse von Barclays:Die Analystin Gena Wang von Barclays bestätigt für die Aktie von Ionis Pharmaceuticals Inc.…

…

…

CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism…

…

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -0.58% and 11.76%, respectively, for the quarter ended December 2024. Do…

…

…

CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism…

…

Agios Pharmaceuticals (AGIO) agrees to sell to Royalty Pharma the rights to royalties on potential net sales of a brain…

The consensus price target hints at a 26% upside potential for Agios Pharmaceuticals (AGIO). While empirical research shows that this…

…

…